Compare · HAE vs MDLN
HAE vs MDLN
Side-by-side comparison of Haemonetics Corporation (HAE) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HAE and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $46.37B, about 14.0x HAE ($3.31B).
- Over the past year, HAE is down 0.2% and MDLN is down 13.3% - HAE leads by 13.1 points.
- MDLN has been more active in the news (18 items in the past 4 weeks vs 7 for HAE).
- Both have 25 recent analyst ratings on file.
- Company
- Haemonetics Corporation
- Medline Inc.
- Price
- $72.92+0.54%
- $35.33+1.87%
- Market cap
- $3.31B
- $46.37B
- 1M return
- +17.76%
- -4.69%
- 1Y return
- -0.24%
- -13.30%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1991
- 2025
- News (4w)
- 7
- 18
- Recent ratings
- 25
- 25
Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Latest HAE
- SEC Form DEFA14A filed by Haemonetics Corporation
- SEC Form DEF 14A filed by Haemonetics Corporation
- VP, Chief Accounting Officer Maunsell Farris Maryanne covered exercise/tax liability with 259 shares, decreasing direct ownership by 4% to 6,242 units (SEC Form 4) (tax withholding)
- SVP, Human Resources Miller Laurie A. covered exercise/tax liability with 313 shares, decreasing direct ownership by 0.76% to 40,987 units (SEC Form 4) (for withholding tax)
- Haemonetics Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Haemonetics Updates Financial Reporting Segments
- Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by Haemonetics Corporation
- Haemonetics upgraded by BofA Securities with a new price target
- SEC Form 10-K filed by Haemonetics Corporation
Latest MDLN
- Officer Abrams William J covered exercise/tax liability with 1,308 shares, decreasing direct ownership by 7% to 16,546 units (SEC Form 4)
- Chief Human Resources Officer Shryock Christopher P covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Operating Officer Miller Stephen L covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Legal Officer Liberman Alexander M. covered exercise/tax liability with 872 shares, decreasing direct ownership by 7% to 11,031 units (SEC Form 4)
- Chief Product Officer Laabs Amanda H. covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Financial Officer Drazin Michael B covered exercise/tax liability with 1,889 shares, decreasing direct ownership by 7% to 23,899 units (SEC Form 4)
- Chief Commercial Officer Golwas Douglas P covered exercise/tax liability with 1,889 shares, converted options into 100,000 shares, sold $3,677,115 worth of shares (100,000 units at $36.77) as part of a pre-agreed trading plan and returned 100,000 units of Class B Common Stock to the company, increasing direct ownership by 1,319% to 365,864 units (SEC Form 4)
- Chief Executive Officer Boyle James M covered exercise/tax liability with 2,370 shares, decreasing direct ownership by 7% to 29,369 units (SEC Form 4)
- Director Galanti Richard A was granted 16,392 shares (SEC Form 4)
- Director Sweet Thomas W was granted 17,800 shares (SEC Form 4)